Galmed Announces Allowance Of New Patent For Aramchol For The Treatment Of Pulmonary And Dermal Fibrosis
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the allowance of a Japanese patent
Galmed Pharmaceuticals Announces Receipt Of Nasdaq Minimum Bid Price Notification
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that the Company received a letter from the
Stocks That Hit 52-Week Lows On Thursday
During Thursday's session, 92 stocks hit new 52-week lows.
Benzinga’s Top Ratings Upgrades, Downgrades For July 24, 2023
Upgrades Maxim Group upgraded the previous rating for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) from Hold to Buy. For the…
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 46 companies set new 52-week lows.
Nasdaq Drops 50 Points; Wells Fargo Earnings Beat Views
U.S. stocks traded mixed toward the end of trading, with the S&P 500 and Nasdaq Composite moving lower on Friday.
The Dow traded up 0.30% to 34,498.91 while the NASDAQ fell 0.36% to 14,087. The S&P 500, also fell, dropping, 0.18% to 4,502.13.
Why State Street Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Gainers
PainReform Ltd. (NASDAQ: PRFX) shares climbed 103% to $11.67. PainReform recently announced pricing of a $2.7 million concurrent registered direct offering and private placement.